NanoSmart Pharmaceuticals, Inc. is a private pharmaceutical company developing novel treatments for cancer and other diseases. The Company has developed and patented a drug delivery platform using human-derived, anti-nuclear antibodies (ANA) capable of targeting many different kinds of solid tumors and inflammatory diseases. The drug delivery platform, which consists of lipid nanoparticles coated with ANA, can be used to encapsulate off-patent FDA-approved drugs to create safer and more effective treatments with extended patent life. The versatility of this platform allows NanoSmart to efficiently pursue a broad drug development pipeline through licensing and partnership opportunities. NanoSmart’s initial focus is on pediatric cancer indications, a patient population that has been traditionally underserved in drug development. The company has obtained orphan drug designation from the FDA for two novel ANA-conjugated nanoparticle drug formulations that are currently in the preclinical phase for the treatment of Ewing’s Sarcoma.